Preoperative Exposure to Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury After Cardiac Surgery: A Retrospective Single-Centre Cohort Study With Overlap Weighting Propensity Score Analysis

This publication has 36 references indexed in Scilit:

• Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users
  JAMA Surgery, 2025
• Dapagliflozin for Critically Ill Patients With Acute Organ Dysfunction
  JAMA, 2024
• Incidence of sodium–glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study
  Journal of Anesthesia, 2024
• Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and the Incidence of Acute Kidney Injury in Taiwan
  JAMA Network Open, 2023
• Empagliflozin Reduces Markers of Acute Kidney Injury in Patients with Acute Decompensated Heart Failure
  ESC Heart Failure, 2022
• Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Reduced or Preserved Ejection Fraction: A Meta-Analysis
  ESC Heart Failure, 2022
• Informing power and sample size calculations when using inverse probability of treatment weighting using the propensity score
  Statistics in Medicine, 2021
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes
  JAMA Cardiology, 2021
• Overlap Weighting
  JAMA, 2020
• Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial
  Intensive Care Medicine, 2017